Reducing medication costs to prevent cardiovascular disease: A community guide systematic review

Preventing Chronic Disease

Volumn 12, Issue 11, 2015, Pages

  Njie, Gibril J ^a   Finnie, Ramona K C ^a   Acharya, Sushama D ^a   Jacob, Verughese ^a   Proia, Krista K ^a   Hopkins, David P ^a   Pronk, Nicolaas P ^b   Goetzel, Ron Z ^c   Kottke, Thomas E ^b   Rask, Kimberly J ^d   Lackland, Daniel T ^e   Braun, Lynne T ^f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

BLOOD; BLOOD PRESSURE; COST BENEFIT ANALYSIS; DEMOGRAPHY; ECONOMICS; HEALTH CARE COST; HUMAN; HYPERLIPIDEMIAS; HYPERTENSION; MEDICATION COMPLIANCE; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA;

BLOOD PRESSURE; CHOLESTEROL; COST-BENEFIT ANALYSIS; HEALTH EXPENDITURES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MEDICATION ADHERENCE; RESIDENCE CHARACTERISTICS;

EID: 84959018674     PISSN: 15451151     EISSN: 21665435     Source Type: Journal    
DOI: 10.5888/pcd12.150242     Document Type: Review

References (48)

1. Centers for Disease Control and Prevention (CDC). Vital signs: awareness and treatment of uncontrolled hypertension among adults - United States, 2003-2010. MMWR Morb Mortal Wkly Rep 2012;61:703-9.
2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25,Suppl 2):S1-45.
3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123(8):933-44.
4. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119(23):3028-35.
5. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010;48(3):196-202.
6. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43(6):521-30.
7. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288(4):455-61.
8. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288(4):462-7.
9. Kennedy J, Morgan S. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries. Clin Ther 2009;31(1):213-9.
10. Soumerai SB, Pierre-Jacques M, Zhang F, Ross-Degnan D, Adams AS, Gurwitz J, et al. Cost-related medication nonadherence among elderly and disabled Medicare beneficiaries: a national survey 1 year before the Medicare drug benefit. Arch Intern Med 2006;166(17):1829-35.
11. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care 2004;42(7):626-34.
12. Briss PA, Zaza S, Pappaioanou M, Fielding J, Wright-De Agüero L, Truman BI, et al.; The Task Force on Community Preventive Services. Developing an evidence-based Guide to Community Preventive Services-methods. Am J Prev Med 2000;18(1, Suppl):35-43.
13. Zaza S, Wright-De Agüero LK, Briss PA, Truman BI, Hopkins DP, Hennessy MH, et al.; The Task Force on Community Preventive Services. Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services. Am J Prev Med 2000;18(1, Suppl):44-74.
14. Baicker K, Mullainathan S, Schwartzstein J. Behavioral hazard in health insurance. Cambridge (MA): National Bureau of Economic Research; 2012. (NBER working paper no. 18468). http://www.nber.org/papers/w18468.pdf. Accessed May 28, 2013.
15. Chandra A, Gruber J, McKnight R. The impact of patient costsharing on low-income populations: evidence from Massachusetts. J Health Econ 2014;33:57-66.
16. Brook RH, Keeler EB, Lohr KN, Newhouse J, Ware J, Rogers W, et al. The health insurance experiment: a classic RAND study speaks to the current health care reform debate. Santa Monica (CA): RAND Corporation, RB-9174-HHS. 2006.
17. World Bank. Country and lending groups; 2012. http://data.worldbank.org/about/country-classifications/country-andlending- groups. Accessed Oct 27, 2015.
18. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119(23):3028-35.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6):1206-52.
20. Alderman MH, Melcher LA. A company-instituted program to improve blood pressure control in primary care. Isr J Med Sci 1981;17(2-3):122-8.
21. Applegate BW, Ames SC, Mehan DJ Jr, McKnight GT, Jones GN, Brantley PJ. Maximizing medication adherence in lowincome hypertensives: a pilot study. J La State Med Soc 2000; 152(7):349-56.
22. Atella V, Peracchi F, Depalo D, Rossetti C. Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients. Health Econ 2006;15(9):875-92.
23. Bunting BA, Smith BH, Sutherland SE. The Asheville Project:clinical and economic outcomes of a community-based longterm medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc (2003) 2008;48(1):23-31.
24. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) 2008;27(1):103-12.
25. Choudhry NK, Fischer MA, Smith BF, Brill G, Girdish C, Matlin OS, et al. Five features of value-based insurance design plans were associated with higher rates of medication adherence. Health Aff (Millwood) 2014;33(3):493-501. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24522551&dopt=Abstract
26. Elhayany A, Vinker S. Addressing healthcare inequities in Israel by eliminating prescription drug copayments. Am J Manag Care 2011; 17(7): e255-9.
27. Farley JF, Wansink D, Lindquist JH, Parker JC, Maciejewski ML. Medication adherence changes following value-based insurance design. Am J Manag Care 2012;18(5):265-74.
28. Gibson TB, Wang S, Kelly E, Brown C, Turner C, Frech-Tamas F, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood) 2011; 30(1):109-17.
29. Haskell WL, Berra K, Arias E, Christopherson D, Clark A, George J, et al. Multifactor cardiovascular disease risk reduction in medically underserved, high-risk patients. Am J Cardiol 2006;98(11):1472-9.
30. Hill MN, Han HR, Dennison CR, Kim MT, Roary MC, Blumenthal RS, et al. Hypertension care and control in underserved urban African American men: behavioral and physiologic outcomes at 36 months. Am J Hypertens 2003; 16(11 Pt 1):906-13.
31. Keeler EB, Brook RH, Goldberg GA, Kamberg CJ, Newhouse JP. How free care reduced hypertension in the health insurance experiment. JAMA 1985;254(14):1926-31.
32. Knott RJ, Petrie DJ, Heeley EL, Chalmers JP, Clarke PM. The effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia. Health Policy 2015;119(5):620-7.
33. Maciejewski ML, Wansink D, Lindquist JH, Parker JC, Farley JF. Value-based insurance design program in north Carolina increased medication adherence but was not cost neutral. Health Aff (Millwood) 2014;33(2):300-8.
34. Musich S, Wang S, Hawkins K. The impact of a value-based insurance design plus health coaching on medication adherence and medical spending. Popul Health Manag 2015;18(3):151-8.
35. Sauvageot J, Kirkpatrick MA, Spray JW. Pharmacistimplemented pharmaceutical manufacturers' assistance programs: effects on health outcomes for seniors. Consult Pharm 2008;23(10):809-12.
36. Trompeter JM, Havrda DE. Impact of obtaining medications from pharmaceutical company assistance programs on therapeutic goals. Ann Pharmacother 2009;43(3):469-77.
37. Wertz D, Hou L, DeVries A, Dupclay L Jr, McGowan F, Malinowski B, et al. Clinical and economic outcomes of the Cincinnati Pharmacy Coaching Program for diabetes and hypertension. Manag Care 2012;21(3):44-54.
38. Kekki P. Assessing the adequacy of antihypertensive treatment in a health centre in finland. J R Coll Gen Pract 1981; 31(225):239-40.
39. Brook RH, Ware JE Jr, Rogers WH, Keeler EB, Davies AR, Donald CA, et al. Does free care improve adults' health? Results from a randomized controlled trial. N Engl J Med 1983;309(23):1426-34.
40. Kelly EJ, Turner CD, Frech-Tamas FH, Doyle JJ, Mauceri EG. Value-based benefit design and health care utilization in asthma, hypertension, and diabetes. Am J Pharm Benefits 2009;1(4):217-21. http://www.ajmc.com/journals/ajpb/2009/iss1_no4/kelly_1-4.
41. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood) 2010;29(11):2002-8.
42. Chernew ME, Juster IA, Shah M, Wegh A, Rosenberg S, Rosen AB, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood) 2010;29(3):530-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20093294&dopt=Abstract
43. Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol 2012;60(18):1817-24.
44. Bureau of Labor Statistics. Consumer Price Index. www.bls.gov/data/. Accessed May 15, 2015.
45. World Bank. World development indicators. 2010. http://data.worldbank.org/indicator. Accessed May 15, 2015.
46. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al. Interventions to improve adherence to selfadministered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012; 157(11):785-95.
47. The Community Preventive Services Task Force. Reducing tobacco use and secondhand smoke exposure: reducing out-ofpocket costs for evidence-based cessation treatments. 2012. http://www.thecommunityguide.org/tobacco/outofpocketcosts.html. Accessed March 3, 2015.
48. The Community Preventive Services Task Force. Recommendation to reduce patients' blood pressure and cholesterol medication costs. Prev Chronic Dis 2015; 12: E209.